The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China; Department of Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
School of Automation Science and Engineering, South China University of Technology, Guangzhou, China.
Clin Breast Cancer. 2021 Aug;21(4):e388-e401. doi: 10.1016/j.clbc.2020.12.004. Epub 2020 Dec 17.
The purpose of this study was to predict pathologic complete response (pCR) to neoadjuvant therapy in breast cancer using radiomics based on pretreatment staging contrast-enhanced computed tomography (CECT).
A total of 215 patients were retrospectively analyzed. Based on the intratumoral and peritumoral regions of CECT images, radiomic features were extracted and selected, respectively, to develop an intratumoral signature and a peritumoral signature with logistic regression in a training dataset (138 patients from November 2015 to October 2017). We also developed a clinical model with the molecular characterization of the tumor. A radiomic nomogram was further constructed by incorporating the intratumoral and peritumoral signatures with molecular characterization. The performance of the nomogram was validated in terms of discrimination, calibration, and clinical utility in an independent validation dataset (77 patients from November 2017 to December 2018). Stratified analysis was performed to develop a subtype-specific radiomic signature for each subgroup.
Compared with the clinical model (area under the curve [AUC], 0.756), the radiomic nomogram (AUC, 0.818) achieved better performance for pCR prediction in the validation dataset with continuous net reclassification improvement of 0.787 and good calibration. Decision curve analysis suggested the nomogram was clinically useful. Subtype-specific radiomic signatures showed improved AUCs (luminal subgroup, 0.936; human epidermal growth factor receptor 2-positive subgroup, 0.825; and triple negative subgroup, 0.858) for pCR prediction.
This study has revealed a predictive value of pretreatment staging-CECT and successfully developed and validated a radiomic nomogram for individualized prediction of pCR to neoadjuvant therapy in breast cancer, which could assist clinical decision-making and improve patient outcome.
本研究旨在利用基于预处理分期增强 CT(CECT)的影像组学预测乳腺癌新辅助治疗的病理完全缓解(pCR)。
共回顾性分析了 215 例患者。基于 CECT 图像的肿瘤内和肿瘤周围区域,分别采用逻辑回归在训练数据集(2015 年 11 月至 2017 年 10 月的 138 例患者)中提取和选择影像组学特征,以开发肿瘤内特征和肿瘤周围特征。我们还根据肿瘤的分子特征建立了临床模型。通过纳入肿瘤内和肿瘤周围特征以及分子特征,进一步构建了放射组学列线图。在 2017 年 11 月至 2018 年 12 月的独立验证数据集(77 例患者)中,验证了列线图的区分度、校准度和临床实用性。通过分层分析,为每个亚组开发了特定的亚组特异性放射组学特征。
与临床模型(曲线下面积 [AUC],0.756)相比,验证数据集中,放射组学列线图(AUC,0.818)在 pCR 预测方面表现更好,连续净重新分类改善为 0.787,校准效果良好。决策曲线分析表明该列线图具有临床实用性。特定的亚组放射组学特征显示出改善的 pCR 预测 AUC(管腔亚组,0.936;人表皮生长因子受体 2 阳性亚组,0.825;三阴性亚组,0.858)。
本研究揭示了预处理分期 CECT 的预测价值,并成功开发和验证了用于预测乳腺癌新辅助治疗 pCR 的放射组学列线图,这可以辅助临床决策并改善患者预后。